Skip to content

PHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS DOCETAXEL IN PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH OR WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG01)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-509865-19-00
Acronym
DS1062-A-U301
Enrollment
261
Registered
2024-07-23
Start date
2021-04-30
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Brief summary

PFS is defined as the time from randomization to the earlier of the dates of the first radiographic disease progression or death due to any cause., OS is defined as the time from randomization to death due to any cause.

Detailed description

PFS is defined as the time from randomization to the earlier of the dates of the first radiographic disease progression or death due to any cause., ORR is defined as the proportion of subjects who achieved a BOR of CR or PR., DoR is defined as the time from the date of the first documentation of objective response (CR or PR) to the date of the first radiographic disease progression or death due to any cause, whichever occurs first., DCR is defined as the proportion of subjects who achieved a BOR of CR, PR, or SD., TTR is defined as the time from randomization to the date of the first documentation of objective response (CR or PR) in responding subjects.

Interventions

DRUGDatopotamab deruxtecan
DRUGDOCETAXEL

Sponsors

Daiichi Sankyo Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
PFS is defined as the time from randomization to the earlier of the dates of the first radiographic disease progression or death due to any cause., OS is defined as the time from randomization to death due to any cause.

Secondary

MeasureTime frame
PFS is defined as the time from randomization to the earlier of the dates of the first radiographic disease progression or death due to any cause., ORR is defined as the proportion of subjects who achieved a BOR of CR or PR., DoR is defined as the time from the date of the first documentation of objective response (CR or PR) to the date of the first radiographic disease progression or death due to any cause, whichever occurs first., DCR is defined as the proportion of subjects who achieved a BOR of CR, PR, or SD., TTR is defined as the time from randomization to the date of the first documentation of objective response (CR or PR) in responding subjects.

Countries

Belgium, France, Germany, Italy, Netherlands, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026